Sanofi and Glaxo Start Human Trials for Covid-19 Vaccine
- Tests are taking place across the U.S. in two age groups
- Companies plan to move into late-stage studies by year-end
This article is for subscribers only.
Sanofi and GlaxoSmithKline Plc, two of the world’s biggest vaccine makers, began testing their experimental Covid-19 shot in the first patients on Thursday and aim to start late-stage trials before year-end.
The drugmakers started human studies at 11 sites across the U.S. The trial — which compresses the early and middle stages of clinical tests — will assess 440 healthy patients in two age groups: 18 to 49, and over 50. Sanofi and Glaxo aim to have results by December, allowing the final stage to begin.